An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families
- McGill Univ., Montreal (Canada)
- Institute of Cancer Research, Surrey (United Kingdom)
- Univ. of Leiden (United Kingdom)
- University Hospital of Iceland, Reykjavik (Iceland)
- Creighton Univ. School of Medicine, Omaha, NE (United States)
- Univ. of Cambridge (United Kingdom)
- Univ. of Michigan School of Medicine, Ann Arbor, MI (United States)
- Dana Farber Cancer Institute, Boston, MA (United States)
- Univ. of Manchester (United Kingdom); and others
The breast-ovary cancer-family syndrome is a dominant predisposition to cancer of the breast and ovaries which has been mapped to chromosome region 17q12-q21. The majority, but not all, of breast-ovary cancer families show linkage to this susceptibility locus, designated BRCA1. We report the results of a linkage analysis of 145 families with both breast and ovarian cancer. These families contain either a total of three or more cases of early-onset (before age 60 years) breast cancer or ovarian cancer. All families contained at least one case of ovarian cancer. Overall, an estimated 76% of the 145 families are linked to the BRCA1 locus. None of the 13 families with cases of male breast cancer appear to be linked, but it is estimated that 92% (95% confidence interval 76%-100%) of families with no male breast cancer and with two or more ovarian cancers are linked to BRCA1. These data suggest that the breast-ovarian cancer-family syndrome is genetically heterogeneous. However, the large majority of families with early-onset breast cancer and with two or more cases of ovarian cancer are likely to be due to BRCA1 mutations. 39 refs., 6 figs., 3 tabs.
- OSTI ID:
- 70391
- Journal Information:
- American Journal of Human Genetics, Journal Name: American Journal of Human Genetics Journal Issue: 1 Vol. 56; ISSN AJHGAG; ISSN 0002-9297
- Country of Publication:
- United States
- Language:
- English
Similar Records
Familial site-specific Ovarian cancer is linked to BRCA1 on 17q12-21
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families